Review offers insight on managing surgical patients who are taking new drugs to prevent blood clots

New oral anticoagulant drugs that treat and prevent clots offer a much-needed alternative to warfarin, which has been used for more than 6 decades and has serious shortcomings. A new article published in BJS (British Journal of Surgery) gives an overview of the major clinical trials and recommendations related to these new agents and will serve as a practical guide for their use in patients who require planned or emergency surgery.

Warfarin has been the of choice to control in a variety of , including people with certain types of irregular heartbeats, people with prosthetic heart valves, and people who have suffered heart attacks. Unfortunately, warfarin has serious side-effects, requires frequent monitoring to reduce the risk of bleeding, and has interactions with multiple drugs and foods. New oral anticoagulant drugs—Apixaban, Dabigatran, and Rivaroxaban —offer safer alternatives to warfarin, but there are currently no markers for measuring activity levels of the drugs and there are no antidotes to reverse or neutralize their effects.

Aida Lai, MBChB, of the North Bristol NHS Trust in the UK, and her colleagues searched the medical literature and analysed studies published between January 2000 and January 2014 that reported on the use of new oral anticoagulant drugs. "As these drugs are still relatively new in the market, knowledge about how they work and their associated bleeding risks are still limited in the medical and surgical community," said Dr Lai. "Our review covers recommendation for the discontinuation of new oral anticoagulant drugs before surgical procedures and resuming of these drugs after procedures." The review also notes that because the drugs are eliminated by the kidneys, they require dose reductions dependent on a patient's kidney function. Also, new oral anticoagulants are not recommended in patients with severe liver dysfunction. And because the three drugs have somewhat different properties, one of the drugs may be better suited to a particular patient than the others.

"It is anticipated that in the near future these drugs would replace to a large extent," said Dr Lai. "Therefore our article is highly relevant to surgeons and any medical professional treating patients on these drugs."

More information: "Perioperative management of patients on new oral anticoagulants." A. Lai, N. Davidson, S. W. Galloway, and J. Thachil. BJS; Published Online: April 29th, 2014 DOI: 10.1002/bjs.9485

add to favorites email to friend print save as pdf

Related Stories

Stroke risk high when anti-clotting drugs stopped

Apr 25, 2012

Some patients with irregular heartbeats who are taken off anti-clotting medication face a high risk of stroke or blood clotting within a month, according to new research presented at the American Heart Association's Emerging ...

Recommended for you

Fluorescent dyes 'light up' brain cancer cells

19 hours ago

Two new fluorescent dyes attracted to cancer cells may help neurosurgeons more accurately localize and completely resect brain tumors, suggests a study in the February issue of Neurosurgery, official journal of the Congre ...

'Vast majority' of neurosurgeons practice defensive medicine

19 hours ago

More than three-fourths US neurosurgeons practice some form of defensive medicine—performing additional tests and procedures out of fear of malpractice lawsuits, reports a special article in the February issue of Neurosurgery, offici ...

Facelift surgery after massive weight loss poses challenges

Jan 29, 2015

Patients undergoing bariatric surgery for severe obesity are often left with excess, sagging skin affecting all areas of the body—including the face. The unique challenges of facelift surgery in this group of patients—and ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.